Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;26(9):2240-2249.
doi: 10.1007/s12094-024-03438-z. Epub 2024 Mar 30.

The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma

Wenjing Xiong #  1 , Liru Li #  1 , Xue Hui  1 , Yue Liu  1 , Hongbin Li  1 , Yue Zhang  2 , Shu Zhao  3
Affiliations

The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma

Wenjing Xiong et al. Clin Transl Oncol. 2024 Sep.

Abstract

Purpose: Metabolic syndrome (MetS), characterized by insulin resistance, is closely associated with the prognosis of various cancer types, but has not been reported in diffuse large B-cell lymphoma (DLBCL). The aim of this study is to examine how other clinicopathological variables and the MetS influence the prognosis of DLBCL.

Methods: Clinical and pathological data were collected from 319 patients with DLBCL who were admitted to our hospital between January 2012 and December 2020. The data accessible with SPSS 27.0 enables the utilization of various statistical methods for clinical data analysis, including independent sample t test and univariate and multivariate COX regression.

Results: The presence of MetS was linked to both overall survival (OS) and progression-free survival (PFS), in addition to other clinicopathological characteristics as age, IPI score, rituximab usage, and Ki-67 expression level. This link with OS and PFS indicated a poor prognosis, as shown by survival analysis. Subsequent univariate analysis identified IPI score, Ki-67 expression level, tumor staging, rituximab usage, lactate dehydrogenase expression level, and the presence or absence of MetS as factors linked with OS and PFS. Furthermore, multivariate Cox regression analysis confirmed the independent risk factor status of IPI score, Ki-67 expression level, rituximab usage, and the presence of MetS in evaluating the prognosis of patients with DLBCL.

Conclusion: This study's findings indicate that patients with pre-treatment MetS had a poor prognosis, with relatively shorter OS and PFS compared to those without pre-treatment MetS. Furthermore, the presence of MetS, IPI score, Ki-67 expression level, and rituximab usage were identified as independent risk factors significantly affecting the prognosis of DLBCL.

Keywords: Diffuse large B-cell lymphoma; Metabolic syndrome; Overall survival; Progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan–Meier analysis of OS A and PFS B according to number of MetS components
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48. 10.3322/caac.21763 - DOI - PubMed
    1. HeKridel MYR. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35(8):2151–65. 10.1038/s41375-021-01285-3 - DOI - PubMed
    1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Nutrition. 1997;13(1):65. 10.1016/s0899-9007(96)00380-2. (discussion 64, 66). 10.1016/s0899-9007(96)00380-2 - DOI - PubMed
    1. AlbertiEckelGrundyZimmetCleemanDonato KGRHSMPZJIKA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–5. 10.1161/circulationaha.109.192644. 10.1161/circulationaha.109.192644 - DOI - PubMed
    1. Feliciano EMC, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. Cancer. 2017;123(13):2535–42. 10.1002/cncr.30637. 10.1002/cncr.30637 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources